{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:41:28Z","timestamp":1792503688932,"version":"4.5.0"},"reference-count":63,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/17474086.2026.2715442","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:10:28Z","timestamp":1785946228000},"page":"1135-1146","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Daratumumab and hyaluronidase-fihj, a monotherapy for high-risk smoldering multiple myeloma: a shift in preventing active myeloma?"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0116-5002","authenticated-orcid":false,"given":"Bartosz","family":"Pu\u0142a","sequence":"first","affiliation":[{"name":"Copernicus Memorial Hospital","place":["\u0141\u00f3d\u017a, Poland"]},{"name":"Medical University of \u0141\u00f3d\u017a","place":["\u0141\u00f3d\u017a, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"Ry\u017cewska","sequence":"additional","affiliation":[{"name":"Copernicus Memorial Hospital","place":["\u0141\u00f3d\u017a, Poland"]},{"name":"Medical University of \u0141\u00f3d\u017a","place":["\u0141\u00f3d\u017a, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Handziuk","sequence":"additional","affiliation":[{"name":"Pozna\u0144 University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Tyczy\u0144ska","sequence":"additional","affiliation":[{"name":"University Clinical Center Gdansk, Medical University of Gda\u0144sk","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Kubicki","sequence":"additional","affiliation":[{"name":"Pozna\u0144 University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00529-7"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02183-6"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e20028"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278519"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070389"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7660"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.07.030"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01740"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01041-x"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409029"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108357"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-088443"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.86"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2026.0831"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04304-x"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01733"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02771"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55308-5"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)02264-3"},{"key":"e_1_3_4_26_1","unstructured":"Nadeem O. Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma. ASH; 2023 [cited 2026 May 26]. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper177954.html"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.5603\/ahp.104091"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210335"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3267"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.achaem.2015.11.003"},{"issue":"1","key":"e_1_3_4_34_1","first-page":"3124","article-title":"Daratumumab in combination with lenalidomide plus dexamethasone results in persistent natural killer (NK) cells with a distinct phenotype and expansion of effector memory T-Cells in Pollux, a phase 3 randomized study","volume":"130","author":"Van De Donk NW","year":"2017","unstructured":"Van De Donk NW, Adams HI, Vanhoof G, et al. Daratumumab in combination with lenalidomide plus dexamethasone results in persistent natural killer (NK) cells with a distinct phenotype and expansion of effector memory T-Cells in Pollux, a phase 3 randomized study. Blood. 2017;130(Sup plement 1):3124.","journal-title":"Blood"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177947"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006866"},{"key":"e_1_3_4_38_1","unstructured":"Nadeem O-B. PRISM (precision intervention smoldering myeloma): a phase II trial of combination of daratumumab bortezomib lenalidomide and dexamethasone in high- risk smoldering multiple myeloma [Internet]. Report No.: NCT04775550. clinicaltrials.gov; 2025 [cited 2026 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04775550"},{"key":"e_1_3_4_39_1","unstructured":"International Myeloma Foundation. Aggressive smoldering Curative approach evaluating novel therapies (ASCENT): a phase 2 trial of induction consolidation and maintenance in subjects with high risk smoldering multiple myeloma (SMM) [Internet]. Report No.: NCT03289299. clinicaltrials.gov; 2023 [cited 2026 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03289299"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025897"},{"key":"e_1_3_4_41_1","unstructured":"Sanofi. A phase 3 randomized open-label multicenter study of Isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma [Internet]. Report No.: NCT04270409. clinicaltrials.gov; 2025 [cited 2026 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04270409"},{"key":"e_1_3_4_42_1","unstructured":"Ghobrial I. A phase II study of the CD38 antibody daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma [Internet]. Report No.: NCT03236428. clinicaltrials.gov; 2026 [cited 2026 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03236428"},{"key":"e_1_3_4_43_1","unstructured":"University College London. Isatuximab and Iberdomide as immunotherapy for high risk in smouldering myeloma [Internet]. Report No.: NCT06762769. clinicaltrials.gov; 2025 [cited 2026 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06762769"},{"key":"e_1_3_4_44_1","unstructured":"National Cancer Institute (NCI). A phase 2 adaptive study of subcutaneous daratumumab once weekly carfilzomib and dexamethasone (DKd) in patients with high-risk smoldering multiple myeloma [Internet]. Report No.: NCT04933539. clinicaltrials.gov; 2026 [cited 2026 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04933539"},{"key":"e_1_3_4_45_1","unstructured":"ECOG-ACRIN Cancer Research Group. Daratumumab to enhance therapeutic effectiveness of revlimid in smoldering myeloma (DETER-SMM) [Internet]. Report No.: NCT03937635. clinicaltrials.gov; 2026 [cited 2026 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03937635"},{"key":"e_1_3_4_46_1","unstructured":"M.D. Anderson Cancer Center. Phase II trial of Isatuximab (SAR650984) with or without lenalidomide in patients with high risk smoldering multiple myeloma (ISAMAR) [Internet]. Report No.: NCT02960555. clinicaltrials.gov; 2026 [cited 2026 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02960555"},{"key":"e_1_3_4_47_1","unstructured":"Landgren CO. Teclistamab or talquetamab in combination with daratumumab SC for high-risk smoldering myeloma: a clinical and correlative phase 2 sequential cohort Immuno-oncology study to REVIVE early myeloma [Internet]. Report No.: NCT06100237. clinicaltrials.gov; 2026 [cited 2026 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06100237"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30081-8"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00940"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00018-X"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02505-2"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279459"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514663"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.5603\/ahp.108054"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.5603\/ahp.103294"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70373"},{"key":"e_1_3_4_62_1","volume-title":"Abstracts of the 30th Congress of the European Hematology Association (EHA 2025); 2025 Jun 12\u201315","author":"Jamroziak K","year":"2025","unstructured":"Jamroziak K, Kubicki T, Dytfeld D, et al. Daratumumab or observation for minimal residual disease reappearance in multiple myeloma: results from the PREDATOR-MRD randomized trial. In: Abstracts of the 30th Congress of the European Hematology Association (EHA 2025); 2025 Jun 12\u201315; Milan, Italy. Abstract S204. EHA Library; 2025. Available from: https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4159281\/krzysztof.jamroziak.daratumumab.or.observation.for.minimal.residual.disease.html"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2026.s2.14042"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0718-z"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04365-y"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2026.2715442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17474086.2026.2715442","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2026.2715442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:02:07Z","timestamp":1792501327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2026.2715442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/17474086.2026.2715442"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2026.2715442","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}